| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Elan Pharmaceuticals |
| Information provided by: | Elan Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00047567 |
Purpose
To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
| Condition | Intervention | Phase |
|
Bipolar Disorders |
Drug: zonisamide |
Phase IV |
| MedlinePlus related topics: | Bipolar Disorder |
| Drug Information available for: | Zonisamide |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Eligibility
| Ages Eligible for Study: | 6 Years to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations More Information
| Study ID Numbers: | ELN-345-509 |
| First Received: | October 8, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00047567 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
